Rapid imaging acquisition, high spatial resolution and sensitivity, powered by
advancements in solid-state detector technology, are significantly changing the perspective …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Diagnostic and therapeutic nuclear medicine relies heavily on radiometal nuclides. The
most widely used and well-known radionuclide is technetium-99m (99mTc), which has …

Targeting overexpressed receptors on the cancer cells with radiolabeled peptides has
become very important in nuclear oncology in the recent years. Peptides are small and have …

Abstract A series of “2+ 1” mixed ligand tricarbonyl complexes of the general formula fac-
[Re/99m Tc/186 Re (CO) 3 (DDTC)(L)] containing diethyldithiocarbamate (DDTC) as a …

With the long-term goal of developing theranostic agents for applications in nuclear
medicine, in this work we evaluated the well-known NOTA and NODAGA chelators as …

Introduction The aim of this work was to develop diagnostic (99m Tc) and therapeutic (186
Re) agents for targeting somatostatin receptor (SSTR)-positive neuroendocrine tumors …

In the present work, we investigated potential means to obtain neutral tricarbonyl mixed-
ligand fac-[M (CO) 3L1L2] complexes (M= Re, 99mTc) containing the (2-hydroxyphenyl) …

Background Somatostatin receptor targeting radiopeptides are successfully being used to
image, stage, and monitor patients with neuroendocrine tumours. They are exclusively …

Recently, radiolabelled antagonists targeting somatostatin receptors subtype 2 (SST2) in
neuroendocrine neoplasms demonstrated certain superior properties over agonists. Within …